Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified class period, alleging misleading statements regarding the company's business and operations [1][3]. Group 1: Lawsuit Details - The lawsuit targets Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements about its prostate cancer therapeutic candidates, supply chain quality, and overall business prospects [3]. - Investors who bought Telix securities between February 21, 2025, and August 28, 2025, are eligible to seek appointment as lead plaintiff representatives by January 9, 2026 [2]. Group 2: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [2]. - Berger Montague, the law firm representing the plaintiffs, has a strong track record in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [4].
ATTENTION TELIX PHARMACEUTICALS (TLX) SHAREHOLDERS: Securities Fraud Lawsuit Filed Against Telix Pharmaceuticals Ltd.